Company Overview
Snapshot
Founded in June 2020 by Orr Inbar and Arnon Horev, QuantHealth operates with 51–200 employees. The company has raised $21.01M across 8 funding rounds from 11 investors. In October 2025, Sanofi Ventures led a strategic investment round to accelerate AI-driven clinical trials.
Business overview
QuantHealth is an AI company focused on accelerating and de-risking drug development through patient-centric drug simulations. Its core technology, an In-Silico platform, enables Clinical Development and Clinical Operations teams to simulate clinical trials in thousands of variations, evaluating parameters for endpoint success, commercial viability, and protocol feasibility. The platform generates synthetic evidence for therapy performance across all clinical phases, leveraging a Large Healthcare Model (LHM) that learns deep patient-drug interactions to drive high-resolution outcome models with 86% endpoint accuracy. QuantHealth serves the pharmaceutical and biotechnology industries, operating within the Health Tech & Life Sciences sector.
Strategic signal
In April 2024, QuantHealth appointed esteemed pharmaceutical executives to its inaugural advisory board. This move signals a strategic intent to strengthen its leadership and expertise in the pharmaceutical domain, likely aiming to enhance market penetration and product development within the drug discovery and development sector, and providing validation of its AI-driven approach to clinical trials.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent strategic investment in QuantHealth?
- In October 2025, QuantHealth secured a strategic investment from Sanofi Ventures to accelerate AI-driven clinical trials.
- What was a notable organizational development for QuantHealth in April 2024?
- In April 2024, QuantHealth appointed esteemed pharmaceutical executives to its inaugural advisory board, enhancing its strategic guidance and industry connections.